PAVMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

PAVmed Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$2.25−0.16 (-6.64%)

Close on Oct 19, 2026

Market cap: $14.11M
P/E (TTM): –
Dividend yield: –

Dividends

PAVmed has not reported a dividend

No dividend per share appears in PAVmed's annual filings since fiscal 2014.

Where these numbers come from

Parsed from the XBRL in PAVmed's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Mar 27, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PAVM.

Revenue growth-89.0% · median 58.2%

Operating margin-23842.9% · median -1891.7%

Net margin-10794.6% · median -2296.7%

Company	Revenue	Growth
LUCD	$5.45M	+24.9%
PAVM	$112.00K	-89.0%
RDGL	$99.10K	+91.5%
GUTS	–	–
PFSA	–	–
QTEX	–	–

Company

Next earnings (est.): Nov 12, 2026, before open
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 3
Held by institutions: 11.7%
Auditor: Marcum LLP
SEC CIK: 1624326

Advertisement
300 × 250